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The role of a reliable data management and information system in
oncology services is well established. In addition to well-known risk
determining factors, the outcome of treatment efforts is also influ-
enced by the geography and genetic makeup of the population being
treated. The toxicity of the therapy used requires closemonitoring of
protocol outcomes to determine the risk benefit. Also advances in di-
agnostic tools and criteria, and identification of new risk factors re-
quire constant update of the data items being collected in such
a system.
Commercially available oncology data management and infor-
mation processing systems are not always useful in fulfilling
these requirements. The initial and maintenance costs for these
programs also make it less feasible for use in resource poor
countries.
Here we report our experience in the successful development
and implementation of a comprehensive, efficient and scalable
data management system specifically developed for hematopoietic
stem cell transplantation of patients with pediatric hematology/
oncology diseases. The data end-users (oncologists and trans-
planters) were critically involved with the system development
and data items incorporated were based on their recommenda-
tions. Ethnic and social characteristics (such as tribal affiliations),
which impact on disease genetics, were also included. The inte-
grated model allows for concentric expansion and linkages that
result in availability of data relating to multiple aspects of each pa-
tient’s care throughout his course, including pre- and post HSCT.
Changes in treatment protocols and diagnostic tests can be easily
incorporated as required. Policies and procedures were developedsimultaneously to direct the workings of this data management
system.
The simplicity, efficiency and scalability of the system design, and
its affordability makes it a model for use in other institutions, espe-
cially in developing countries.93
IMPLEMENTATION OF HEMATOLOGY-ONCOLOGY LECTURE SERIES FOR
HOUSESTAFF
Steinberg, A.S. Cedars-Sinai Medical Center, Los Angeles, CA
Background: We have a ward service dedicated to cancer patients.
Housestaff taking care of these patients includes three interns and
a fellow. There is also a consult service comprising a fellow, an in-
tern, and a resident. There is a need to implement formal, didactic,
teaching devoted to topics in hematology and oncology to improve
quality of care.
Objective: The development of a monthly lecture series for house-
staff rotating on a hematology-oncology rotation focusing on three
key areas:
a) Knowledge tomanage the patients on the hematology-oncology
service
b) What one is most likely to encounter in the practice of medi-
cine, regardless of eventual subspecialty field.
c) Relevance for Internal Medicine exams.
Methods: Topics chosen based on relevance included leukemia,
lymphoma, multiple myeloma, transplantation (these first four
comprising .75% of patients on service), coagulation, breast can-
cer, lung cancer, colon cancer, gynecological cancer, and pain
management/supportive care. Speakers included full-time faculty
as well as private physicians affiliated with the cancer center.
Emails and phone calls were placed to the physicians and an-
nouncements made at division meetings and schedules developed.
Test questions were given to housestaff at the start of their one
month rotation and at the end of rotation. Lectures were sched-
uled for afternoons if possible to avoid conflicts with morning
rounds. Occasional morning talks were necessary however due
to schedule issues. Format of lectures was flexible (power point,
dry-eraser board).
Results:Overall feedback was positive for the lectures. The two con-
ditions affecting optimal success of the program concerned schedul-
ing, including housestaff schedules and availability of when and
which speakers could lecture. The question/answer testing is early
in the process.
Conclusion: A didactic lecture series is an important aspect of stem
cell hematology-oncology education for housestaff and will improve
quality of care of the stem cell transplant service. Repeating lectures
every month is a challenge for several reasons. Possible interventions
in the future may include:
a) Focusing lecturing duties to full-time faculty, with an emphasis
on faculty currently on service
b) Creating power point presentations and handouts on file for use
by multiple people so that rotating faculty may use these materials
for talks
c) Statistical analysis of scores from pre-rotation and post-rotation
exams to assess housestaff performancePHARMACY ORAL
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THE EFFICACY OF APREPITANT ADDED TO ONDANSETRON AND DEXA-
METHASONE FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA
AND VOMITING (CINV) DURING AUTOLOGOUS HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT)
Augustin, K.M.1, Hladnik, L.M.1, Dietz, R.2, Gabriel, J.3, Vij, R.3,
Cashen, A.F.3, Stockerl-Goldstein, K.3, Abboud, C.N.3, Nobbe, J.A.1,
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Despite premedication with dexamethasone and ondansetron,
acute and delayed CINV remains a persistent problem in the set-
ting of autologous HSCT. Aprepitant is an oral neurokinin-1
